SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced Richard Pascoe, Chief Executive Officer, will present at the Biotech Showcase 2015 Conference on Monday, January 12, 2015 at 3:30 p.m. Pacific Time. The conference will be held at the Parc 55 Wyndham Hotel in San Francisco, CA. Mr. Pascoe will provide an update on the European launch of Vitaros®, the Company's topical treatment for erectile dysfunction, as well as an overview of Apricus' drug candidates Fispemifene and RayVa™.
A live audio webcast of the presentation can be accessed via the Investor Relations section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 90 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus' lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus' marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus' second-generation Vitaros Room Temperature Device is under development and is expected to enhance the product's commercial value. Apricus recently commenced a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon. Additionally, Apricus plans to initiate a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of male secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms. Apricus is currently seeking a strategic partner to fund development of Femprox®, a product candidate for the treatment of female sexual interest/arousal disorder that completed an approximately 400-subject proof-of-concept study.
For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Institutional Investors: Angeli Kolhatkar firstname.lastname@example.org Burns McClellan (212) 213-0006 Retail Investors: Chris Eddy, David Collins email@example.com Catalyst Global (212) 924-9800
Source:Apricus Biosciences, Inc.